PFE

A surge in U.S.-China transactions is drawing scrutiny in Washington, where some lawmakers are pushing to slow the pace of investment.

MRK's Keytruda plus Padcev combo gets CHMP backing as perioperative treatment for eligible patients with resectable muscle-invasive bladder cancer.

Pfizer remains a compelling income play, offering a 6.22% yield and trading at 9.3x 2026 consensus EPS amid a rising-rate environment. PFE's non-COVID portfolio is growing 5% operationally, with robust pipeline activity and $1.5B ahead of the original 2026 base business guidance. Management targets $9.7B in cost savings by 2029, supporting dividend coverage through the patent cliff and enabling R&D investment.

Pfizer has made significant progress in addressing some of its challenges. However, the company still has a rocky road ahead.

Pfizer (PFE +0.07%) has experienced unprecedented circumstances in the previous decade.

Pfizer has a deep pipeline that could help improve its approved lineup and financial results over the medium term. Abbott Laboratories' core medical device business remains strong, and the company has attractive opportunities elsewhere.

Pfizer's free cash flow is not covering its dividend, and the company faces a patent cliff. Energy Transfer is one of the biggest beneficiaries of strong natural demand coming from the AI data center build-out.

Pfizer has raised its dividend every year for over a decade, then something changed. Before you count on that 6% yield, find out what the payout's own behavior is quietly signaling about the company's financial confidence.

Pfizer's management remains firmly committed to maintaining the dividend. The company's growth portfolio is performing well.

Where you hold a high-yield dividend stock matters almost as much as which one you pick, and for ordinary-income payers like BDCs and REITs, the wrong account quietly erodes a portion of every distribution before it ever compounds.